The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan
Open accessAbstract
In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has been limited to the management of its symptoms and complications. Recently, the US Food and Drug Administration (FDA) approved tolvaptan as the first drug treatment to slow kidney function decline in adults at risk of rapidly progressing ADPKD. Full prescribing information approved by the FDA provides helpful guidelines but does not address practical questions that are being raised by nephrologists, internists, and general practitioners taking care of patients with ADPKD, and by the patients themselves. In this review, we provide practical guidance and discuss steps that require consideration before and after prescribing tolvaptan to patients with ADPKD to ensure that this treatment is implemented safely and effectively. These steps include confirmation of diagnosis; identification of rapidly progressive disease; implementation of basic renal protective measures; counseling of patients on potential benefits and harms; exclusions to use; education of patients on aquaresis and its expected consequences; initiation, titration, and optimization of tolvaptan treatment; prevention of aquaresis-related complications; evaluation and management of liver enzyme elevations; and monitoring of treatment efficacy. Our recommendations are made on the basis of published evidence and our collective experiences during the randomized, clinical trials and open-label extension studies of tolvaptan in ADPKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205511 · Cited by 1,614
Self-citationYao, Q., Wu, M., Zhou, J., Zhou, M., Chen, D., Fu, L., Bian, R., Xing, X., Sun, L., Hu, X., et al. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000474961 · Cited by 847
Volume Progression in Polycystic Kidney Disease
Grantham, J. J., Torres, V. E., Chapman, A. B., Guay-Woodford, L. M., Bae, K. T., King, B. F., Wetzel, L. H., Baumgarten, D. A., Kenney, P. J., Harris, P. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054341 · Cited by 807
Self-citationUnified Criteria for Ultrasonographic Diagnosis of ADPKD
Pei, Y., Obaji, J., Dupuis, A., Paterson, A. D., Magistroni, R., Dicks, E., Parfrey, P., Cramer, B., Coto, E., Torra, R., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008050507 · Cited by 762
Johnson, R. J., Bakris, G. L., Borghi, C., Chonchol, M. B., Feldman, D., Lanaspa, M. A., Merriman, T. R., Moe, O. W., Mount, D. B., Sanchez Lozada, L. G., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.12.009 · Cited by 644
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Perrone, R. D., Koch, G., Ouyang, J., McQuade, R. D., Blais, J. D., Czerwiec, F. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1710030 · Cited by 639
Self-citationIrazabal, M. V., Rangel, L. J., Bergstralh, E. J., Osborn, S. L., Harmon, A. J., Sundsbak, J. L., Bae, K. T., Chapman, A. B., Grantham, J. J., Mrug, M., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013101138 · Cited by 625
Self-citationChapman, A. B., Devuyst, O., Eckardt, K.-U., Gansevoort, R. T., Harris, T., Horie, S., Kasiske, B. L., Odland, D., Pei, Y., Perrone, R. D., et al. (2015) · Kidney International · doi:10.1038/ki.2015.59 · Cited by 611
Self-citationType of PKD1 Mutation Influences Renal Outcome in ADPKD
Cornec-Le Gall, E., Audrézet, M.-P., Chen, J.-M., Hourmant, M., Morin, M.-P., Perrichot, R., Charasse, C., Whebe, B., Renaudineau, E., Jousset, P., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070650 · Cited by 530
Porath, B., Gainullin, V. G., Cornec-Le Gall, E., Dillinger, E. K., Heyer, C. M., Hopp, K., Edwards, M. E., Madsen, C. D., Mauritz, S. R., Banks, C. J., et al. (2016) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2016.05.004 · Cited by 475
Self-citationGenetic Complexity of Autosomal Dominant Polycystic Kidney and Liver Diseases
Cornec-Le Gall, E., Torres, V. E., & Harris, P. C. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017050483 · Cited by 406
Self-citationKidney Volume and Functional Outcomes in Autosomal Dominant Polycystic Kidney Disease
Chapman, A. B., Bost, J. E., Torres, V. E., Guay-Woodford, L., Bae, K. T., Landsittel, D., Li, J., King, B. F., Martin, D., Wetzel, L. H., et al. (2012) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09500911 · Cited by 378
Self-citationCornec-Le Gall, E., Audrézet, M.-P., Rousseau, A., Hourmant, M., Renaudineau, E., Charasse, C., Morin, M.-P., Moal, M.-C., Dantal, J., Wehbe, B., et al. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015010016 · Cited by 359
Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease
Cornec-Le Gall, E., Olson, R. J., Besse, W., Heyer, C. M., Gainullin, V. G., Smith, J. M., Audrézet, M.-P., Hopp, K., Porath, B., Shi, B., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2018.03.013 · Cited by 312
Self-citationVasopressin Directly Regulates Cyst Growth in Polycystic Kidney Disease
Wang, X., Wu, Y., Ward, C. J., Harris, P. C., & Torres, V. E. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007060688 · Cited by 286
Self-citationAutosomal dominant polycystic kidney disease: the changing face of clinical management
Ong, A. C. M., Devuyst, O., Knebelmann, B., & Walz, G. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60907-2 · Cited by 280
Gansevoort, R. T., Arici, M., Benzing, T., Birn, H., Capasso, G., Covic, A., Devuyst, O., Drechsler, C., Eckardt, K.-U., Emma, F., et al. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv456 · Cited by 255
Rossetti, S., Burton, S., Strmecki, L., Pond, G. R., San Millán, J. L., Zerres, K., Barratt, T. M., Ozen, S., Torres, V. E., Bergstralh, E. J., et al. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000013300.11876.37 · Cited by 218
Self-citationIsolated polycystic liver disease genes define effectors of polycystin-1 function
Besse, W., Dong, K., Choi, J., Punia, S., Fedeles, S. V., Choi, M., Gallagher, A.-R., Huang, E. B., Gulati, A., Knight, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90129 · Cited by 203
Self-citationWatkins, P. B., Lewis, J. H., Kaplowitz, N., Alpers, D. H., Blais, J. D., Smotzer, D. M., Krasa, H., Ouyang, J., Torres, V. E., Czerwiec, F. S., et al. (2015) · Drug Safety · doi:10.1007/s40264-015-0327-3 · Cited by 194
Self-citationTorres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Perrone, R. D., Dandurand, A., Ouyang, J., Czerwiec, F. S., Blais, J. D., & for the TEMPO 4:4 Trial Investigators (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx043 · Cited by 185
Self-citationImaging-Based Diagnosis of Autosomal Dominant Polycystic Kidney Disease
Pei, Y., Hwang, Y.-H., Conklin, J., Sundsbak, J. L., Heyer, C. M., Chan, W., Wang, K., He, N., Rattansingh, A., Atri, M., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014030297 · Cited by 178
Self-citationTorres, V. E., Higashihara, E., Devuyst, O., Chapman, A. B., Gansevoort, R. T., Grantham, J. J., Perrone, R. D., Ouyang, J., Blais, J. D., Czerwiec, F. S., et al. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06300615 · Cited by 171
Self-citationKline, T. L., Korfiatis, P. D., Edwards, M. E., Blais, J. D., Czerwiec, F. S., Harris, P. C., King, B. F., Torres, V. E., & Erickson, B. J. (2017) · Journal of Imaging Informatics in Medicine · doi:10.1007/s10278-017-9978-1 · Cited by 167
Self-citationGenotype-Renal Function Correlation in Type 2 Autosomal Dominant Polycystic Kidney Disease
Magistroni, R., He, N., Wang, K., Andrew, R., Johnson, A., Gabow, P. A., Dicks, E. L., Parfrey, P. S., Torrá, R., San‐Millán, J. L., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000061774.90975.25 · Cited by 157
Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Three Years' Experience
Higashihara, E., Torres, V. E., Chapman, A. B., Grantham, J. J., Bae, K. T., Watnick, T. J., Horie, S., Nutahara, K., Ouyang, J., Krasa, H. B., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03530411 · Cited by 152
Self-citationVasopressin-V2 Receptor Stimulation Reduces Sodium Excretion in Healthy Humans
Bankir, L., Fernandes, S., Bardoux, P., Bouby, N., & Bichet, D. G. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004121079 · Cited by 138
Recent Advances in the Management of Autosomal Dominant Polycystic Kidney Disease
Chebib, F. T., & Torres, V. E. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03960318 · Cited by 136
Self-citationPerrone, R. D., Mouksassi, S., Romero, K., Czerwiec, F. S., Chapman, A. B., Gitomer, B. Y., Torres, V. E., Miskulin, D. C., Broadbent, S., & Marier, J. (2017) · Kidney International Reports · doi:10.1016/j.ekir.2017.01.003 · Cited by 129
Self-citationO'Neill, W. C., Robbin, M. L., Bae, K. T., Grantham, J. J., Chapman, A. B., Guay‐Woodford, L. M., Torres, V. E., King, B. F., Wetzel, L. H., Thompson, P. A., et al. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.08.026 · Cited by 113
Self-citationYu, A. S. L., Shen, C., Landsittel, D. P., Harris, P. C., Torres, V. E., Mrug, M. M., Bae, K. T., Grantham, J. J., Rahbari-Oskoui, F. F., Flessner, M. F., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.09.027 · Cited by 109
Self-citationUric acid lowering therapies for preventing or delaying the progression of chronic kidney disease
Sampson, A. L., Singer, R. F., & Walters, G. D. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009460.pub2 · Cited by 101
Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease
Edwards, M. E., Chebib, F. T., Irazabal, M. V., Ofstie, T. G., Bungum, L. A., Metzger, A. J., Senum, S. R., Hogan, M. C., Zoghby, Z., Kline, T. L., et al. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01520218 · Cited by 100
Self-citationWoodhead, J. L., Brock, W. J., Roth, S. E., Shoaf, S. E., Brouwer, K. L. R., Church, R. J., Grammatopoulos, T. N., Stiles, L., Siler, S. Q., Howell, B. A., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw193 · Cited by 96
Boertien, W. E., Meijer, E., de Jong, P. E., Bakker, S. J. L., Czerwiec, F. S., Struck, J., Oberdhan, D., Shoaf, S. E., Krasa, H. B., & Gansevoort, R. T. (2013) · Kidney International · doi:10.1038/ki.2013.285 · Cited by 91
Aihara, M., Fujiki, H., Mizuguchi, H., Hattori, K., Ohmoto, K., Ishikawa, M., Nagano, K., & Yamamura, Y. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213256 · Cited by 71
Irazabal, M. V., Abebe, K. Z., Bae, K. T., Perrone, R. D., Chapman, A. B., Schrier, R. W., Yu, A. S. L., Braun, W. E., Steinman, T. I., Harris, P. C., et al. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw294 · Cited by 65
Self-citationTorres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Perrone, R. D., Dandurand, A., Ouyang, J., Czerwiec, F. S., Blais, J. D., & for the TEMPO 4:4 Trial Investigators (2017) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx079 · Cited by 65
Self-citationAmro, O. W., Paulus, J. K., Noubary, F., & Perrone, R. D. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.07.023 · Cited by 64
Self-citationOberdhan, D., Cole, J. C., Krasa, H. B., Cheng, R., Czerwiec, F. S., Hays, R. D., Chapman, A. B., & Perrone, R. D. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.08.020 · Cited by 55
Self-citationIrazabal, M. V., Blais, J. D., Perrone, R. D., Gansevoort, R. T., Chapman, A. B., Devuyst, O., Higashihara, E., Harris, P. C., Zhou, W., Ouyang, J., et al. (2016) · Kidney International Reports · doi:10.1016/j.ekir.2016.08.001 · Cited by 54
Self-citationGall, É. C.-L., Chebib, F. T., Madsen, C. D., Senum, S. R., Heyer, C. M., Lanpher, B. C., Patterson, M. C., Albright, R. C., Yu, A. S. L., Torres, V. E., et al. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.11.015 · Cited by 42
Self-citationSemiautomated Segmentation of Polycystic Kidneys in T2-Weighted MR Images
Kline, T. L., Edwards, M. E., Korfiatis, P. D., Akkus, Z., Torres, V. E., & Erickson, B. J. (2016) · American Journal of Roentgenology · doi:10.2214/ajr.15.15875 · Cited by 41
Self-citationShoaf, S. E., Chapman, A. B., Torres, V. E., Ouyang, J., & Czerwiec, F. S. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.880 · Cited by 40
Self-citationSoroka, S., Alam, A., Bevilacqua, M. U., Girard, L., Komenda, P. V. J., Loertscher, R., McFarlane, P. A., Pandeya, S., Tam, P. Y., & Bichet, D. G. (2017) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358117695784 · Cited by 33
Regulation of renal Na-(K)-Cl cotransporters by vasopressin
Bachmann, S., & Mutig, K. (2017) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-017-2002-2 · Cited by 33
Perrone, R. D., Neville, J., Chapman, A. B., et al. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.04.044 · Cited by 26
Self-citationCase report: a thiazide diuretic to treat polyuria induced by tolvaptan
Kramers, B. J., van Gastel, M. D. A., Meijer, E., & Gansevoort, R. T. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0957-7 · Cited by 23
Edwards, M. E., Blais, J. D., Czerwiec, F. S., Erickson, B. J., Torres, V. E., & Kline, T. L. (2018) · Clinical Kidney Journal · doi:10.1093/ckj/sfy078 · Cited by 16
Self-citationGirardat-Rotar, L., Braun, J., Puhan, M. A., Abraham, A. G., & Serra, A. L. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0654-y · Cited by 13
Genomic Analysis to Avoid Misdiagnosis of Adults With Bilateral Renal Cysts
Gulati, A., Bae, K. T., Somlo, S., & Watnick, T. J. (2018) · Annals of Internal Medicine · doi:10.7326/l17-0644 · Cited by 11
Self-citation
Cited by
Bergmann, C., Guay-Woodford, L. M., Harris, P. C., Horie, S., Peters, D. J. M., & Torres, V. E. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0047-y · Cited by 807
Self-citationAutosomal dominant polycystic kidney disease
Cornec-Le Gall, E., Alam, A., & Perrone, R. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32782-x · Cited by 624
Self-citationCiliopathies and the Kidney: A Review
McConnachie, D. J., Stow, J. L., & Mallett, A. J. (2021) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.08.012 · Cited by 257
Metadata
- Authors
- Chebib, F. T., Perrone, R. D., Chapman, A. B., Dahl, N. K., Harris, P. C., Mrug, M., Mustafa, R. A., Rastogi, A., Watnick, T., Yu, A. S. L., & Torres, V. E.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2018-09-18
- Volume
- 29
- Issue
- 10
- Pages
- 2458-2470
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- OpenAlex
- W2891820180
- Cited by
- 257
- References
- 51
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.